Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT

Watchlist Manager
Arcturus Therapeutics Holdings Inc Logo
Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
Watchlist
Price: 7.3 USD 2.38% Market Closed
Market Cap: 207.4m USD

Arcturus Therapeutics Holdings Inc
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Arcturus Therapeutics Holdings Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
Pre-Tax Income
-$66.7m
CAGR 3-Years
23%
CAGR 5-Years
-5%
CAGR 10-Years
-12%
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$1.7B
CAGR 3-Years
-52%
CAGR 5-Years
-27%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$9.9B
CAGR 3-Years
30%
CAGR 5-Years
41%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$8.2B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$4.4B
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5.1B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
16%
No Stocks Found

Arcturus Therapeutics Holdings Inc
Glance View

Market Cap
198.8m USD
Industry
Biotechnology

Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. The company is headquartered in San Diego, California and currently employs 177 full-time employees. The company went IPO on 2013-05-22. The firm is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its mRNA platform, the Company's lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose levels. The firm's products under developmental stage using STARR technology are ARCT-021, ARCT-154 and ARCT-165. Its COVID-19 vaccine candidate, ARCT-021, which is based on its STARR technology platform is through Phase II clinical trials. Its LUNAR-FLU Vaccine consists of Liver Franchise ARCT-810 (LUNAR-OTC) and Lung Franchise ARCT-032 (LUNAR-CF).

ARCT Intrinsic Value
25.28 USD
Undervaluation 71%
Intrinsic Value
Price

See Also

What is Arcturus Therapeutics Holdings Inc's Pre-Tax Income?
Pre-Tax Income
-66.7m USD

Based on the financial report for Sep 30, 2025, Arcturus Therapeutics Holdings Inc's Pre-Tax Income amounts to -66.7m USD.

What is Arcturus Therapeutics Holdings Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-12%

Over the last year, the Pre-Tax Income growth was -7%. The average annual Pre-Tax Income growth rates for Arcturus Therapeutics Holdings Inc have been 23% over the past three years , -5% over the past five years , and -12% over the past ten years .

Back to Top